Skip to Content

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCBRE1391


A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Principal Investigator(s)

Ingrid Mayer


  • Protocol No. VICCBRE1391
  • Open Date: 04/24/2014
  • Staging: Phase III
  • Age Group: Adults
  • Scope: International
  • Objective: The primary objective of this study is to compare progression-free survival (PFS), as assessed by blinded central review, of patients with advanced/metastatic HER2-negative gBRCAmut breast cancer when treated with niraparib as compared to those treated with physician's choice single agent chemotherapy standards (eribulin, vinorelbine, gemcitabine or capecitabine).
  • Disease Sites: Breast
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Capecitabine; Gemcitabine; Halaven (eribulin); Niraparib; Vinorelbine
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01905592
  • Secondary Protocol No: TESARO PR-30-5010-C


None Provided.


Not provided. Please call for more information.